Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,705,896
  • Shares Outstanding, K 1,629,285
  • Annual Sales, $ 22,561 M
  • Annual Income, $ 4,920 M
  • 60-Month Beta 0.73
  • Price/Sales 4.52
  • Price/Cash Flow 15.24
  • Price/Book 6.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.89
  • Number of Estimates 3
  • High Estimate 0.90
  • Low Estimate 0.87
  • Prior Year 0.94
  • Growth Rate Est. (year over year) -5.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.55 +6.67%
on 01/03/20
67.21 -0.73%
on 01/17/20
+2.61 (+4.07%)
since 12/17/19
3-Month
52.38 +27.38%
on 10/18/19
67.21 -0.73%
on 01/17/20
+14.30 (+27.28%)
since 10/17/19
52-Week
42.48 +57.06%
on 07/23/19
67.21 -0.73%
on 01/17/20
+17.12 (+34.52%)
since 01/17/19

Most Recent Stories

More News
Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BMY : 66.72 (-0.09%)
BMY or AZN: Which Is the Better Value Stock Right Now?

BMY vs. AZN: Which Stock Is the Better Value Option?

BMY : 66.72 (-0.09%)
AZN : 51.33 (+1.62%)
Is Bristol-Myers Squibb (BMY) a Good Stock to Pick Now?

Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.

BMY : 66.72 (-0.09%)
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

MRK : 90.97 (-0.23%)
JNJ : 149.17 (+0.65%)
BMY : 66.72 (-0.09%)
ABBV : 88.00 (-1.41%)
AZN : 51.33 (+1.62%)
NVS : 95.93 (+0.87%)
LLY : 139.58 (-1.31%)
J&J Seeks Label Expansion for Spravato Nasal Spray in EU

J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

BMY : 66.72 (-0.09%)
LLY : 139.58 (-1.31%)
AGN : 192.68 (-0.59%)
JNJ : 149.17 (+0.65%)
New Study Indicates 'Helper' Cells May Kill Cancerous Tumors

USA News Group - A new study out suggests that T cells are a subset of lymphocytes (white blood cells), which play a key role in the body's immune response. This new information could prove to be a key...

ALNY : 118.82 (-0.44%)
ONCY : 3.10 (-2.52%)
ONC.TO : 3.93 (-2.96%)
BMY : 66.72 (-0.09%)
AEMD : 2.06 (-25.36%)
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy

Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy

BMY : 66.72 (-0.09%)
BCS : 9.12 (-1.51%)
VLO : 91.22 (-0.83%)
GCO : 43.14 (-1.12%)
GHG : 13.60 (+0.74%)
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

MRK : 90.97 (-0.23%)
BMY : 66.72 (-0.09%)
LLY : 139.58 (-1.31%)
PFE : 40.51 (-0.25%)
Just - Evotec Biologics Announces Product Development And Manufacturing Agreement With Oncoresponse

JUST - EVOTEC BIOLOGICS WILL APPLY ITS FULLY INTEGRATED TECHNOLOGY PLATFORM IN ORDER TO ACCELERATE ONCORESPONSE'S LEAD PRODUCT CANDIDATE THROUGH DEVELOPMENT AND INTO THE CLINIC

ARE : 162.90 (-0.56%)
BMY : 66.72 (-0.09%)
NVS : 95.93 (+0.87%)
NVO : 61.31 (unch)
Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

LLY : 139.58 (-1.31%)
BMY : 66.72 (-0.09%)
GILD : 62.98 (-0.35%)
NKTR : 22.48 (-5.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 67.39
1st Resistance Point 67.05
Last Price 66.72
1st Support Level 66.54
2nd Support Level 66.37

See More

52-Week High 67.21
Last Price 66.72
Fibonacci 61.8% 57.76
Fibonacci 50% 54.85
Fibonacci 38.2% 51.93
52-Week Low 42.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar